

# **MWG Biotech / Eurofins Medigenomix upgrade to a Genome Sequencer FLX for sequencing services**

**Munich, Germany, July 12, 2007. MWG Biotech AG/ Eurofins Medigenomix GmbH have successfully upgraded their Genome Sequencer 20 from Roche to the next generation Genome Sequencer FLX system.**

MWG Biotech/Eurofins Medigenomix were the first international service providers in Germany to offer their customers access to the next generation DNA sequencing technology via the Roche Genome Sequencer (GS) 20 system. Since the installation of the system at fall of last year, the companies have already been able to finalize numerous sequencing projects for academic, industrial and pharmaceutical research institutions worldwide.

The companies' sequencing platform is based on the combination of classical Sanger sequencing and sequencing-by-synthesis technology, supported by customized bioinformatics, which allows them to sequence and compare bacterial genomes in only a couple of days.

Through the FLX upgrade, the companies will continue to increase cost-effectiveness and set new standards in velocity for whole genome sequencing and a wide range of genome analysis applications. The companies' major goal is to maintain its high standard service capabilities, while offering state-of-the art technology to their customers.

Whilst the GS 20 system delivers 200.000 sequence reads with an average read length of 100 – 120 base pairs in a single run, the next generation GS FLX system increases the throughput fivefold. It is now possible to sequence 400.000 reads with an average read length of 220 – 250 base pairs, resulting in 100 million base pairs generated in only 7.5 hours and with higher accuracy per individual read and at the consensus level.

Georg Gradl, Sales Manager Sequencing Europe, says: "Based on the experience with the GS 20 in the last months and in combination with additional software tools and processes developed in-house, it is now possible to serve our customers in an even more cost effective and time efficient way."

## **About MWG Biotech**

MWG Biotech AG, headquartered in Ebersberg, Germany, is an international provider of DNA sequencing services, DNA/siRNA synthesis products, Gene Synthesis and bioinformatic services for academic and industrial research. With production sites in Germany, the US and India, the company's strength is its strong customer orientation, fast service and high quality products including a series of advanced oligonucleotide and siRNA design tools. In August 2005, the company joined forces with Eurofins Medigenomix GmbH.

For further information, please visit the corporate website at: [www.mwg-biotech.com](http://www.mwg-biotech.com).

### **About Eurofins Medigenomix**

Eurofins Medigenomix GmbH, located in Martinsried, Germany is an innovative bioanalytical company, specialized in services for DNA analysis. The business unit for DNA sequencing and molecular biology applications is well known as outsourcing partner for the biopharmaceutical industry and academic institutions, the unit for Applied Genetics is a leading provider for DNA forensics, paternity testing in humans and animals and authenticity testing in food. A special strength of Medigenomix' team is the extensive experience in purifying and handling DNA samples from different origin for various applications in DNA analysis. For further information, please visit the corporate website at: [www.medigenomix.com](http://www.medigenomix.com).

**For further information, please contact:**

**MWG Biotech AG**  
**Dr. Jutta Huber**  
**Phone +49 8092 8289-930**  
**Email [jhuber@mwgdna.com](mailto:jhuber@mwgdna.com)**

**Eurofins Medigenomix GmbH**  
**Dr. Tobias Wagner**  
**Phone +49 89899892-13**  
**Email [wagner@medigenomix.de](mailto:wagner@medigenomix.de)**